Abstract
PCV8 Cost-Effectiveness and Budget Impact Analysis of Rivaroxaban in the Prevention of Thromboembolic Events in Patients Performing Hip and Knee Arthroplasty in Comparison with Dabigatran Under the Brazilian Private Health Care System Perspective
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
